Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
(WorldNews Switzerland)

Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on OCREVUS® (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)...